WO2009111623A3 - Tartrate de varénicline amorphe - Google Patents

Tartrate de varénicline amorphe Download PDF

Info

Publication number
WO2009111623A3
WO2009111623A3 PCT/US2009/036157 US2009036157W WO2009111623A3 WO 2009111623 A3 WO2009111623 A3 WO 2009111623A3 US 2009036157 W US2009036157 W US 2009036157W WO 2009111623 A3 WO2009111623 A3 WO 2009111623A3
Authority
WO
WIPO (PCT)
Prior art keywords
varenicline tartrate
amorphous
amorphous varenicline
tartrate
processes
Prior art date
Application number
PCT/US2009/036157
Other languages
English (en)
Other versions
WO2009111623A2 (fr
Inventor
Subba Reddy Peddireddy
Arjun Kumar Tummala
Jaydeepkumar Dahyabhai Lilakar
Srirami Reddy Kikkuru
Ramchandra Reddy Pingili
Srinivasan Neti
Swarupa Dudipala
Madhu Raju Veera Boina
Ramalinga Reddy Beeravalli
Sundara Lakshmi Kanniah
Vamsee Krishna Muppidi
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Priority to EP09716470A priority Critical patent/EP2262780A4/fr
Publication of WO2009111623A2 publication Critical patent/WO2009111623A2/fr
Publication of WO2009111623A3 publication Critical patent/WO2009111623A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne le tartrate de varénicline amorphe, des dispersions solides amorphes de tartrate de varénicline et un excipient pharmaceutique, et leurs procédés de préparation.
PCT/US2009/036157 2008-03-06 2009-03-05 Tartrate de varénicline amorphe WO2009111623A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09716470A EP2262780A4 (fr) 2008-03-06 2009-03-05 Tartrate de varénicline amorphe

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN571CH2008 2008-03-06
IN571/CHE/2008 2008-03-06
US7384408P 2008-06-19 2008-06-19
US61/073,844 2008-06-19

Publications (2)

Publication Number Publication Date
WO2009111623A2 WO2009111623A2 (fr) 2009-09-11
WO2009111623A3 true WO2009111623A3 (fr) 2009-12-10

Family

ID=41056650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036157 WO2009111623A2 (fr) 2008-03-06 2009-03-05 Tartrate de varénicline amorphe

Country Status (2)

Country Link
EP (1) EP2262780A4 (fr)
WO (1) WO2009111623A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2801842A1 (fr) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Co-precipites amorphes de tartrate de varenicline
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CN104478803A (zh) * 2014-12-19 2015-04-01 连云港恒运医药科技有限公司 伐尼克兰中间体及其硝基还原杂质的制备方法
US11266658B2 (en) * 2017-03-03 2022-03-08 Ctc Bio, Inc. Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092089A1 (fr) * 2001-05-14 2002-11-21 Pfizer Products Inc. Sels de tartrate de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US6558435B2 (en) * 2000-05-26 2003-05-06 Pfizer, Inc. Reactive crystallization method to improve particle size
WO2007012963A1 (fr) * 2005-07-26 2007-02-01 Pfizer Products Inc. Système transdermique pour la varenicline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
JP2008516942A (ja) * 2004-10-15 2008-05-22 ファイザー・プロダクツ・インク バレニクリンの鼻腔内、バッカル、舌下および肺送達のための組成物および方法
EP1843769A1 (fr) * 2005-01-07 2007-10-17 Pfizer Products Incorporated Formes posologiques a desintegration rapide de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558435B2 (en) * 2000-05-26 2003-05-06 Pfizer, Inc. Reactive crystallization method to improve particle size
WO2002092089A1 (fr) * 2001-05-14 2002-11-21 Pfizer Products Inc. Sels de tartrate de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
WO2007012963A1 (fr) * 2005-07-26 2007-02-01 Pfizer Products Inc. Système transdermique pour la varenicline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIAURA, RAYMOND ET AL.: "Varenicline", NATURE REVIEWS DRUG DISCOVERY, vol. 5, no. 7, 2006, pages 537 - 538, XP008138247 *
See also references of EP2262780A4 *

Also Published As

Publication number Publication date
EP2262780A2 (fr) 2010-12-22
EP2262780A4 (fr) 2012-01-25
WO2009111623A2 (fr) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2011051971A3 (fr) Dispersion solide de rifaximine
WO2010030598A3 (fr) Formulations pharmaceutiques comprenant du pemetrexed
WO2010117738A3 (fr) Formes à l'état solide de sels de sitagliptine
GB0715896D0 (en) Microporous polymers, methods for the preparation thereof, and uses thereof
IL207993A0 (en) Amorphous lenalidomide, solid dispersions comprising the same and processes for producing the same
WO2010031720A3 (fr) Nouvelle formulation d’anticorps
ZA200808365B (en) Dicyclooctane derivates, preparation processes and pharmaceutical uses thereof
WO2006127941A3 (fr) Hydrochlorure de cinacalcet amorphe et sa preparation
WO2008021342A3 (fr) Formes cristallines de la 9-hydroxy-rispéridone (palipéridone)
WO2010015657A3 (fr) Nouveaux alcoxypyrazoles
WO2010056656A3 (fr) Synthèse de chlorhydrate de palonosétron cristallin
EP2504938A4 (fr) Procédés, systèmes et dispositifs permettant de fournir une interconnexion à l'aide de fibre optique jusqu'au bureau de l'utilisateur
WO2011006002A3 (fr) Nanostructures recouvertes de métal et procédés associés
EP4349369A3 (fr) Augmentation de la biodisponibilité de médicaments dans une thérapie par naltrexone
WO2009111623A3 (fr) Tartrate de varénicline amorphe
WO2009004593A3 (fr) Procédés de préparation d'épinéphrine
WO2014076712A3 (fr) Dispersion solide de chlorhydrate de lurasidone
EP2439308A4 (fr) Procédé de cémentation d'un élément en tantale et élément en tantale
WO2008051539A3 (fr) Processus de préparation de sels de palonosetron
WO2009152167A3 (fr) Administration d'agents thérapeutiques
EP2396497A4 (fr) Procédé d'utilisation d'un dispositif de retenue et dispositif de retenue
WO2009026257A8 (fr) Procédés et compositions pour contrôler la biodisponibilité de médicaments faiblement solubles
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
WO2010028105A3 (fr) Disodium de pemetrexed amorphe
WO2010039885A3 (fr) Formes cristallines du dexlansoprazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09716470

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009716470

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5066/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE